Mallinckrodt’s SpecGx division has announced the rejection of its abuse-deterrent re-formulation of opioid analgesic Roxicodone by the US Food and Drug Administration (FDA).
News
Circassia takes on full US rights to AZ’ Tudorza
Circassia Pharmaceuticals is exercising an option to acquire the full US commercial rights to AstraZeneca’s Tudorza.
New NICE standards to improve digital health tech uptake
The National Institute for Health and Care Excellence has published new standards setting out the requirements needed to develop digital health technologies for the NHS, to accelerate uptake of products like healthcare apps and wearable devices.
Launch of largest ever UK lung cancer screening study
The largest ever lung cancer screening project undertaken in the UK has launched in London, aiming to detect lung cancer early among at-risk citizens.
Oxford BioTherapeutics, WuXi Biologics team up to create cancer antibodies
Oxford BioTherapeutics has entered a strategic partnership with WuXi Biologics to develop bispecific antibodies for the treatment of several cancer types, expanding on the existing collaboration between the two.
PredictSURE IBD gains CE mark, set for UK and EU launch
PredictImmune is gearing up to launch its novel prognostic test for inflammatory disease after it was awarded a CE mark.
Scientists develop revolutionary tech to improve prostate cancer detection
A ‘revolutionary’ new medical software able to pinpoint the area from which surgeons should take a biopsy to detect prostate cancer has been developed by NIHR supported researchers.
NHS risks losing revenue without data strategy
Think tank Reform has warned that the National Health Service risks losing out on huge potential revenue in the future if it does not put in place a strategy to capitalise on the increasing value of its medical data.
Roche’s Daniel O’Day to become Gilead’s chief executive
Gilead Sciences has announced that Daniel O’Day, the current CEO of Roche’s pharmaceutical unit, will become their chief executive effective from March 1 next year. Daniel will replace current CEO John Milligan, after Gilead revealed that John will step down at the end of 2018.
AI app decreases symptoms of COPD, study finds
A new clinical study has found that Kaia Health’s artificial intelligence app successfully decreases symptoms of Chronic Obstructive Pulmonary Disease (COPD).
SMC accepts four medicines for NHS use
Roche’s Perjeta, a medicine used to treat early stage breast cancer, has been accepted by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland.
Health secretary orders review of overprescribing
Health secretary Matt Hancock has ordered a review of patients who take multiple medicines, to ensure they are receiving the most appropriate treatment for their needs, and avoid needless overprescribing.
Pfizer UK names new managing director
Pfizer has announced the appointment of Ben Osborn as managing director in the UK, taking over from Erik Nordkamp, who will now become general manager UK and cluster lead Europe within Pfizer’s Established Medicines business.
Cancer Research and AstraZeneca launch genomics centre
Cancer Research UK and AstraZeneca have announced that they are opening a new centre in Cambridge, UK, dedicated to realising the full potential of functional genomics in the discovery and development of new drugs for patients with cancer.
Pharma calls for more detail on plan for post Brexit meds access
The pharmaceutical industry is calling on the government to urgently provide more detail on how it plans to ensure a continued supply of medicines should the UK leave the EU under a ‘no-deal’ scenario.
